NCT07253688 Adjunctive Rifampin for the Treatment of Prosthetic Valve Endocarditis Due to S. Aureus
| NCT ID | NCT07253688 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Todd C. Lee MD MPH FIDSA |
| Condition | Staphylococcus Aureus Endocarditis |
| Study Type | INTERVENTIONAL |
| Enrollment | 330 participants |
| Start Date | 2025-11-10 |
| Primary Completion | 2029-12 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
This is a sub-study of the S. aureus Network Adaptive Platform (SNAP) trial (NCT05137119) wherein we will evaluate whether not giving rifampin in patients with probable or definite prosthetic valve endocarditis due to S. aureus is non-inferior to giving rifampin.
Eligibility Criteria
Inclusion Criteria: 1. Probable or definite prosthetic valve endocarditis involving the tricuspid, pulmonic, mitral and/or aortic valves by the 2023 Duke-ISCVID Criteria (including Cardiac PET evidence if applicable); 2. Patient or healthcare proxy provide informed consent. Exclusion Criteria: 1. Death deemed imminent and inevitable within days or patient will be receiving palliative care and has prognosis \< 90 days according to the treating team; 2. Patient requires intensive care but has a do not resuscitate order precluding transfer; 3. Polymicrobial bacteremia (not including skin commensals or other recognized contaminant); 4. Organism tests as rifampin resistant; 5. History of hypersensitivity/anaphylaxis or severe adverse reaction to rifampin; 6. Category X or other important drug-drug interaction with rifampin which cannot be safely mitigated \[with as-needed consultation from experts from pharmacy and/or internal medicine/geriatrics for potential deprescribing\]; 7. Child Pugh